FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032174639> ?p ?o ?g. }

• W3032174639 endingPage "366" @default.
• W3032174639 startingPage "362" @default.
• W3032174639 abstract "ObjectiveTo determine the influence of abiraterone acetate (AA) on neuroendocrine differentiation (NED) in metastatic castration-resistant prostate cancer (mCRPC) and the prognostic predicting value of the serum NED markers in mCRPC patients treated with AA.MethodsWe conducted an analysis in 115 chemotherapy-naive mCRPC patients who were treated with chemotherapy in Renji hospital from 2013 to 2017. The median age was 70, ranged from 65 to 76 years old. The median CgA, NSE and PSA levels were 101.1 ng/ml(78.5-150.0 ng/ml), 13.4 ng/ml(10.5-17.6 ng/ml)and 38.8 ng/ml(11.2-123.2 ng/ml), respectively. Among them, 48 cases were classified as the group without AA treatment. The other 67 cases were classified as group after AA failure. In group without AA treatment, the median CgA, NSE and PSA levels were 109.1 ng/ml(80-151.5 ng/ml); 13.8 ng/ml(10.8-18.2 ng/ml)and 39.2 ng/ml(8.6-200 ng/ml), respectively. In group after AA failure, the median CgA, NSE and PSA levels were 105.4 ng/ml(78.8-175.5 ng/ml), 13.8 ng/ml(10.8-17.6 ng/ml)and 39.0 ng/ml(8.4-219.8 ng/ml), respectively. In the group with serial evaluation of NED markers during AA treatment, the median serum CgA, NSE levels at baseline were 115.9 ng/ml(90.1-201.5 ng/ml), 13.3 ng/ml(10.4-18.1 ng/ml), respectively. The endpoints were PSA PFS(progression-free survival) and radiographic PFS(rPFS).ResultsIn 34 patients with serial evaluation, serum NED markers level in 19 patients increased after the failure of AA treatment. Median serum CgA and NSE levels were 115.9 ng/ml(90.1-201.5 ng/ml) and 13.25 ng/ml (10.37-18.14 ng/ml)at baseline. Median serum CgA and NSE levels were 129.6 ng/ml (75.5-230.5 ng/ml) and 14.7 ng/ml(11.8-19.1 ng/ml) after 6 months treatment, respectively. The median serum CgA and NSE levels were 130.4 ng/ml (95.7-205.7 ng/ml) and 15.2 ng/ml(12.4-18.7 ng/ml) at the time of failure of AA treatment, respectively. There was no significant difference of NED markers between baseline and failure of AA treatment (P=0.243). In logistic univariate analysis, AA treatment and its duration were not independent factors influencing NED(P=0.30; P=0.52). Compared with the NED markers elevation group in the first 6 months of AA treatment and baseline supranormal NED markers group, the NED markers decline group(PSA PFS(17.1 vs. 10.4 months, P<0.001)and rPFS(17.0 vs. 10.4 months, P=0.003)) and baseline normal NED markers group(PSA PFS(14.1 vs. 9.5 months, P=0.001)and rPFS(16.4 vs. 10.5 months, P<0.001)) has a longer median PSA PFS and rPFS respectively. In multivariate Cox analysis, baseline NED markers level and NED markers variation during the first 6 months of AA treatment remained significant predictors of rPFS(P<0.05), and PSA-PFS(P<0.05).ConclusionsWe found there was heterogeneity in changes of NED markers in different mCRPC patients during AA treatment, and AA might not significantly lead to progression of NED of mCRPC in general. Serial CgA and NSE evaluation might help clinicians guide clinical treatment of mCRPC patients. Serum NED markers elevation during the first 6 months of AA treatment and elevated baseline NED markers levels indicated poor prognosis in mCRPC treated with AA.Key words: Abiraterone acetate; Neuroendocrine differentiation; Chemotherapy naive; Castration-resistant prostate cancer" @default.
• W3032174639 created "2020-06-05" @default.
• W3032174639 creator A5006041868 @default.
• W3032174639 creator A5008154260 @default.
• W3032174639 creator A5009027431 @default.
• W3032174639 creator A5011198446 @default.
• W3032174639 creator A5013129340 @default.
• W3032174639 creator A5016243869 @default.
• W3032174639 creator A5016942534 @default.
• W3032174639 creator A5025036258 @default.
• W3032174639 creator A5027842973 @default.
• W3032174639 creator A5031010935 @default.
• W3032174639 creator A5033614956 @default.
• W3032174639 creator A5050531186 @default.
• W3032174639 creator A5057863237 @default.
• W3032174639 creator A5065349005 @default.
• W3032174639 creator A5072195107 @default.
• W3032174639 date "2018-05-15" @default.
• W3032174639 modified "2023-09-24" @default.
• W3032174639 title "Serum levels of neuroendocrine differentiation markers predict the prognosis of patients with metastatic castration resistant prostate cancer treated with abiraterone acetate" @default.
• W3032174639 doi "https://doi.org/10.3760/cma.j.issn.1000-6702.2018.05.010" @default.
• W3032174639 hasPublicationYear "2018" @default.
• W3032174639 type Work @default.
• W3032174639 sameAs 3032174639 @default.
• W3032174639 citedByCount "0" @default.
• W3032174639 crossrefType "journal-article" @default.
• W3032174639 hasAuthorship W3032174639A5006041868 @default.
• W3032174639 hasAuthorship W3032174639A5008154260 @default.
• W3032174639 hasAuthorship W3032174639A5009027431 @default.
• W3032174639 hasAuthorship W3032174639A5011198446 @default.
• W3032174639 hasAuthorship W3032174639A5013129340 @default.
• W3032174639 hasAuthorship W3032174639A5016243869 @default.
• W3032174639 hasAuthorship W3032174639A5016942534 @default.
• W3032174639 hasAuthorship W3032174639A5025036258 @default.
• W3032174639 hasAuthorship W3032174639A5027842973 @default.
• W3032174639 hasAuthorship W3032174639A5031010935 @default.
• W3032174639 hasAuthorship W3032174639A5033614956 @default.
• W3032174639 hasAuthorship W3032174639A5050531186 @default.
• W3032174639 hasAuthorship W3032174639A5057863237 @default.
• W3032174639 hasAuthorship W3032174639A5065349005 @default.
• W3032174639 hasAuthorship W3032174639A5072195107 @default.
• W3032174639 hasConcept C121608353 @default.
• W3032174639 hasConcept C126322002 @default.
• W3032174639 hasConcept C126894567 @default.
• W3032174639 hasConcept C2775832370 @default.
• W3032174639 hasConcept C2776694085 @default.
• W3032174639 hasConcept C2777899217 @default.
• W3032174639 hasConcept C2780192828 @default.
• W3032174639 hasConcept C71924100 @default.
• W3032174639 hasConcept C90924648 @default.
• W3032174639 hasConceptScore W3032174639C121608353 @default.
• W3032174639 hasConceptScore W3032174639C126322002 @default.
• W3032174639 hasConceptScore W3032174639C126894567 @default.
• W3032174639 hasConceptScore W3032174639C2775832370 @default.
• W3032174639 hasConceptScore W3032174639C2776694085 @default.
• W3032174639 hasConceptScore W3032174639C2777899217 @default.
• W3032174639 hasConceptScore W3032174639C2780192828 @default.
• W3032174639 hasConceptScore W3032174639C71924100 @default.
• W3032174639 hasConceptScore W3032174639C90924648 @default.
• W3032174639 hasIssue "5" @default.
• W3032174639 hasLocation W30321746391 @default.
• W3032174639 hasOpenAccess W3032174639 @default.
• W3032174639 hasPrimaryLocation W30321746391 @default.
• W3032174639 hasRelatedWork W1898749913 @default.
• W3032174639 hasRelatedWork W2052926537 @default.
• W3032174639 hasRelatedWork W2082140610 @default.
• W3032174639 hasRelatedWork W2085738216 @default.
• W3032174639 hasRelatedWork W2088384001 @default.
• W3032174639 hasRelatedWork W2139855987 @default.
• W3032174639 hasRelatedWork W2162697934 @default.
• W3032174639 hasRelatedWork W2256307172 @default.
• W3032174639 hasRelatedWork W2358338039 @default.
• W3032174639 hasRelatedWork W2391255580 @default.
• W3032174639 hasRelatedWork W2565543081 @default.
• W3032174639 hasRelatedWork W2900902431 @default.
• W3032174639 hasRelatedWork W2908575644 @default.
• W3032174639 hasRelatedWork W2967560936 @default.
• W3032174639 hasRelatedWork W2996231784 @default.
• W3032174639 hasRelatedWork W3030274092 @default.
• W3032174639 hasRelatedWork W3030966113 @default.
• W3032174639 hasRelatedWork W3031554787 @default.
• W3032174639 hasRelatedWork W3148191686 @default.
• W3032174639 hasRelatedWork W3173978065 @default.
• W3032174639 hasVolume "39" @default.
• W3032174639 isParatext "false" @default.
• W3032174639 isRetracted "false" @default.
• W3032174639 magId "3032174639" @default.
• W3032174639 workType "article" @default.